Induction of the Epithelial-to-Mesenchymal Transition of Human Colorectal Cancer by Human TNF-β (Lymphotoxin) and its Reversal by Resveratrol.
Biomarkers, Tumor
Cell Line, Tumor
Cell Membrane
Cell Movement
/ drug effects
Cell Survival
/ drug effects
Colorectal Neoplasms
/ metabolism
Down-Regulation
Epithelial-Mesenchymal Transition
/ drug effects
Focal Adhesion Kinase 1
/ metabolism
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Lymphotoxin-alpha
/ pharmacology
NF-kappa B
Receptors, Tumor Necrosis Factor
Resveratrol
/ pharmacology
NF-κB
TNF-β (lymphotoxin α)
colorectal cancer
epithelial-to-mesenchymal-transition (EMT)
resveratrol
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
26 Mar 2019
26 Mar 2019
Historique:
received:
26
02
2019
revised:
19
03
2019
accepted:
21
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
9
8
2019
Statut:
epublish
Résumé
Tumor necrosis factor-beta (TNF-β), as an inflammatory mediator that has been shown to promote tumorigenesis, induces NF-κB. Natural multi-targeted agent resveratrol in turn shows anti-inflammatory and anti-cancer properties. Epithelial-to-mesenchymal transition (EMT) allows cancer cells to turn into a motile state with invasive capacities and is associated with metastasis and development of cancer stem cells (CSC). However, TNF-β-induced EMT and the anti-invasion mechanism of resveratrol on CRC are not yet completely understood. We investigated the underlying molecular mechanisms of resveratrol on TNF-β/TNF-βR-induced EMT and migration of CRC cells (HCT116, RKO, SW480) in monolayer or 3D alginate cultures. TNF-β, similar to TNF-α, induced significant cell proliferation, morphological change, from an epithelial to a spindle-like mesenchymal shape with the formation of filopodia and lamellipodia associated with the expression of EMT parameters (elevated vimentin and slug, reduced E-cadherin), increased migration/invasion, and formation of CSC in all CRC cells. Interestingly, these effects were dramatically decreased in the presence of resveratrol or anti-TNF-βR with TNF-β co-treatment, inducing biochemical changes to the mesenchymal-epithelial transition (MET), with a planar cell surface and suppressed formation of CSC cells. This was associated with a significant increase in apoptosis. Furthermore, we found that resveratrol suppressed TNF-β-induced NF-κB and NF-κB-regulated gene biomarkers associated with growth, proliferation, and invasion. Finally, TNF-βR interacts directly with focal adhesion kinase (FAK) and NF-κB. These results suggest that resveratrol down-regulates TNF-β/TNF-βR-induced EMT, at least in part via specific suppression of NF-κΒ and FAK in CRC cells.
Identifiants
pubmed: 30917533
pii: nu11030704
doi: 10.3390/nu11030704
pmc: PMC6471988
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Lymphotoxin-alpha
0
NF-kappa B
0
Receptors, Tumor Necrosis Factor
0
Focal Adhesion Kinase 1
EC 2.7.10.2
PTK2 protein, human
EC 2.7.10.2
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Références
Prog Biophys Mol Biol. 1999;71(3-4):435-78
pubmed: 10354709
Mol Cell Biol. 1999 Aug;19(8):5785-99
pubmed: 10409765
Nat Rev Mol Cell Biol. 2000 Nov;1(2):91-100
pubmed: 11253370
Eur Cytokine Netw. 2001 Mar;12(1):87-96
pubmed: 11282551
Semin Cancer Biol. 2001 Apr;11(2):119-28
pubmed: 11322831
FEBS Lett. 2001 Jun 15;499(1-2):176-81
pubmed: 11418135
Trends Cell Biol. 2002 Mar;12(3):112-20
pubmed: 11859023
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Immunity. 2002 Oct;17(4):525-35
pubmed: 12387745
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
J Biol Chem. 2003 Apr 4;278(14):12006-12
pubmed: 12556537
Curr Med Chem Anticancer Agents. 2003 Mar;3(2):77-93
pubmed: 12678904
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
World J Gastroenterol. 2004 Oct 15;10(20):3048-52
pubmed: 15378791
Cancer Cell. 2004 Sep;6(3):203-8
pubmed: 15380510
J Korean Med Sci. 2004 Oct;19(5):710-5
pubmed: 15483349
Immunol Rev. 2004 Dec;202:49-66
pubmed: 15546385
J Immunol. 2005 Jan 1;174(1):21-5
pubmed: 15611222
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
J Cell Biol. 2006 Mar 27;172(7):973-81
pubmed: 16567498
Biochem Pharmacol. 2006 Nov 30;72(11):1605-21
pubmed: 16889756
Cancer Metastasis Rev. 2006 Sep;25(3):409-16
pubmed: 16951987
Nature. 2007 Nov 29;450(7170):712-6
pubmed: 18046409
Curr Protoc Mol Biol. 2001 May;Chapter 10:Unit 10.16
pubmed: 18265056
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Br J Pharmacol. 2009 Jun;157(3):436-50
pubmed: 19371341
Clin Cancer Res. 2009 May 15;15(10):3557-67
pubmed: 19447876
J Cell Mol Med. 2009 Jul;13(7):1314-20
pubmed: 19604316
Immunobiology. 2009;214(9-10):761-77
pubmed: 19616341
Future Oncol. 2009 Oct;5(8):1129-43
pubmed: 19852726
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):650-5
pubmed: 20406206
BMC Cancer. 2011 Apr 12;11:130
pubmed: 21486440
Proteome Sci. 2011 Aug 17;9(1):49
pubmed: 21849056
Biosci Rep. 2012 Feb;32(1):1-15
pubmed: 21981137
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Mol Cancer Res. 2012 Aug;10(8):1109-19
pubmed: 22707636
Oral Oncol. 2012 Nov;48(11):1068-75
pubmed: 22766510
Cancer Res. 2013 Apr 15;73(8):2418-27
pubmed: 23436798
J Pathol. 2014 Jan;232(1):43-56
pubmed: 24014111
Biochem Biophys Res Commun. 2013 Nov 29;441(4):891-6
pubmed: 24211585
Hybridoma. 1987 Oct;6(5):489-507
pubmed: 2445655
Mol Nutr Food Res. 2014 Jul;58(7):1389-401
pubmed: 24659233
J Immunol Res. 2014;2014:149185
pubmed: 24901008
J Biol Chem. 2014 Aug 8;289(32):22048-62
pubmed: 24962570
Semin Cell Dev Biol. 2014 Dec;36:224-31
pubmed: 25239399
J Cancer Res Clin Oncol. 2015 Oct;141(10):1697-713
pubmed: 25270087
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
BMC Cancer. 2015 Apr 10;15:250
pubmed: 25884903
Am J Cancer Res. 2015 Apr 15;5(5):1680-91
pubmed: 26175937
Biochem Pharmacol. 2015 Nov 1;98(1):51-68
pubmed: 26310874
Acta Pharm Sin B. 2014 Jun;4(3):173-81
pubmed: 26579381
Exp Ther Med. 2015 Nov;10(5):1725-1731
pubmed: 26640543
Nutrients. 2016 Mar 05;8(3):145
pubmed: 26959057
Cell Physiol Biochem. 2016;39(6):2203-2215
pubmed: 27832627
Cold Spring Harb Symp Quant Biol. 2016;81:11-19
pubmed: 28057845
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Med Oncol. 2017 Jul;34(7):122
pubmed: 28560682
Semin Cancer Biol. 2017 Oct;46:158-181
pubmed: 28823533
Nutrients. 2017 Sep 27;9(10):null
pubmed: 28953264
Nutrients. 2018 Jul 12;10(7):null
pubmed: 30002278
Mol Med. 2018 Jun 5;24(1):29
pubmed: 30134816
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Semin Cancer Biol. 2018 Nov 22;:null
pubmed: 30472212
Int J Cancer. 2019 Jun 15;144(12):2992-3000
pubmed: 30536395
Exp Biol Med (Maywood). 2019 Jan;244(1):1-12
pubmed: 30661394
J Biol Chem. 1996 Oct 4;271(40):24934-8
pubmed: 8798772
Cell Biol Int. 1997 Feb;21(2):75-86
pubmed: 9080655
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2460-5
pubmed: 9122217
Int J Biochem Cell Biol. 1997 Dec;29(12):1433-48
pubmed: 9570137
Front Biosci. 1999 Jan 15;4:D102-13
pubmed: 9889179